☰

Daniel A. Haber - Publications

Affiliations: 
Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA, United States 
Tree Info Grants Similar researchers PubMed Report error

322 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, ... ... Haber DA, et al. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Biorxiv : the Preprint Server For Biology. PMID 38559183 DOI: 10.1101/2024.03.13.583573  0.36
2024 Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, Kusaka E, Otani YS, Badusi PO, Smith MR, Meneely E, Olivier K, Lowe AC, Toner M, Maheswaran S, ... Haber DA, et al. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 8: e2300230. PMID 38354328 DOI: 10.1200/PO.23.00230  0.635
2023 Takahashi M, Chong HB, Zhang S, Lazarov MJ, Harry S, Maynard M, White R, Murrey HE, Hilbert B, Neil JR, Gohar M, Ge M, Zhang J, Durr BR, Kryukov G, ... ... Haber DA, et al. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Biorxiv : the Preprint Server For Biology. PMID 37961514 DOI: 10.1101/2023.10.20.563287  0.571
2023 Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, ... ... Haber DA, et al. Germline mutations and developmental mosaicism underlying -mutant lung cancer. Medrxiv : the Preprint Server For Health Sciences. PMID 37808694 DOI: 10.1101/2023.09.28.23296274  0.35
2023 Guo H, Vuille JA, Wittner BS, Lachtara EM, Hou Y, Lin M, Zhao T, Raman AT, Russell HC, Reeves BA, Pleskow HM, Wu CL, Gnirke A, Meissner A, Efstathiou JA, ... ... Haber DA, et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell. PMID 37327786 DOI: 10.1016/j.cell.2023.05.028  0.735
2023 Fox DB, Ebright RY, Hong X, Russell HC, Guo H, LaSalle TJ, Wittner BS, Poux N, Vuille JA, Toner M, Hacohen N, Boland GM, Sen DR, Sullivan RJ, Maheswaran S, ... Haber DA, et al. Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. Npj Precision Oncology. 7: 25. PMID 36864091 DOI: 10.1038/s41698-023-00362-3  0.301
2023 Matsuda S, Revandkar A, Dubash TD, Ravi A, Wittner BS, Lin M, Morris R, Burr R, Guo H, Seeger K, Szabolcs A, Che D, Nieman L, Getz GA, Ting DT, ... ... Haber DA, et al. TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state. Cell Reports. 42: 112129. PMID 36821441 DOI: 10.1016/j.celrep.2023.112129  0.548
2022 Micalizzi DS, Che D, Nicholson BT, Edd JF, Desai N, Lang ER, Toner M, Maheswaran S, Ting DT, Haber DA. Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. Proceedings of the National Academy of Sciences of the United States of America. 119: e2209563119. PMID 36256815 DOI: 10.1073/pnas.2209563119  0.304
2022 Burr R, Edd JF, Chirn B, Mishra A, Haber DA, Toner M, Maheswaran S. Negative-Selection Enrichment of Circulating Tumor Cells from Peripheral Blood Using the Microfluidic CTC-iChip. Methods in Molecular Biology (Clifton, N.J.). 2471: 309-321. PMID 35175606 DOI: 10.1007/978-1-0716-2193-6_18  0.302
2022 Karabacak NM, Zheng Y, Dubash TD, Burr R, Micalizzi DS, Wittner BS, Lin M, Wiley DF, Comaills V, Emmons E, Niederhoffer KL, Ho U, Ukleja J, Che D, Stowe H, ... ... Haber DA, et al. Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition. Cancer Research. PMID 35045985 DOI: 10.1158/0008-5472.can-21-2609  0.748
2021 Guo H, Golczer G, Wittner BS, Langenbucher A, Zachariah M, Dubash TD, Hong X, Comaills V, Burr R, Ebright RY, Horwitz E, Vuille JA, Hajizadeh S, Wiley DF, Reeves BA, ... ... Haber DA, et al. NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer. Molecular Cell. 81: 4041-4058.e15. PMID 34624217 DOI: 10.1016/j.molcel.2021.09.016  0.565
2021 Micalizzi DS, Ebright RY, Haber DA, Maheswaran S. Translational Regulation of Cancer Metastasis. Cancer Research. PMID 33479028 DOI: 10.1158/0008-5472.CAN-20-2720  0.324
2020 Mishra A, Dubash TD, Edd JF, Jewett MK, Garre SG, Karabacak NM, Rabe DC, Mutlu BR, Walsh JR, Kapur R, Stott SL, Maheswaran S, Haber DA, Toner M. Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 32641515 DOI: 10.1073/Pnas.2006388117  0.393
2020 Franses JW, Philipp J, Missios P, Bhan I, Liu A, Yashaswini C, Tai E, Zhu H, Ligorio M, Nicholson B, Tassoni EM, Desai N, Kulkarni AS, Szabolcs A, Hong TS, ... ... Haber DA, et al. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nature Communications. 11: 3303. PMID 32620742 DOI: 10.1038/S41467-020-17150-3  0.406
2020 Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, ... ... Haber DA, et al. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32571788 DOI: 10.1158/1078-0432.Ccr-20-0638  0.614
2020 Mutlu BR, Dubash T, Dietsche C, Mishra A, Ozbey A, Keim K, Edd JF, Haber DA, Maheswaran S, Toner M. In-flow measurement of cell-cell adhesion using oscillatory inertial microfluidics. Lab On a Chip. PMID 32301448 DOI: 10.1039/D0Lc00089B  0.395
2020 Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, ... ... Haber DA, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 580: 245-251. PMID 32269342 DOI: 10.1038/S41586-020-2140-0  0.367
2020 Lee S, Micalizzi D, Truesdell SS, Bukhari SIA, Boukhali M, Lombardi-Story J, Kato Y, Choo MK, Dey-Guha I, Ji F, Nicholson BT, Myers DT, Lee D, Mazzola MA, Raheja R, ... ... Haber DA, et al. A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. Genome Biology. 21: 33. PMID 32039742 DOI: 10.1186/S13059-020-1936-4  0.579
2020 Ebright RY, Lee S, Wittner BS, Niederhoffer KL, Nicholson BT, Bardia A, Truesdell S, Wiley DF, Wesley B, Li S, Mai A, Aceto N, Vincent-Jordan N, Szabolcs A, Chirn B, ... ... Haber DA, et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science (New York, N.Y.). PMID 32029688 DOI: 10.1126/Science.Aay0939  0.469
2020 Kalinich M, Kwan TT, Toner M, Haber DA, Maheswaran S. Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 215: 77-88. PMID 31605224 DOI: 10.1007/978-3-030-26439-0_4  0.472
2020 Haber D, Hong X, Ebright R, Micalizi D, Bardia A, Sullivan R, Toner M, Maheswaran S. Abstract IA18: Molecular signatures of circulating tumor cells Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-Ia18  0.518
2020 Dubash TD, Bardia A, Reeves BA, Chirn B, Szabolcs A, Wittner BS, Iafrate J, Ting D, Patel HK, Bihani T, Toner M, Haber DA, Maheswaran S. Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-01-06  0.43
2020 Vidula N, Horick N, Basile E, Sutherland S, Fax R, Haber D, Ellisen L, Rugo HS, Bardia A. Abstract OT2-03-03: Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: Genotyping based clinical trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot2-03-03  0.394
2020 Hong X, Roh W, Sullivan RJ, Wong KH, Wittner BS, Guo H, Dubash TD, Sade-Feldman M, Wesley BK, Boland GM, Marvin DL, Bonesteel T, Lu C, Horwitz E, Aguet F, ... ... Haber DA, et al. Abstract 6073: The lipogenic regulatorSREBPinducesTransferrinin circulating melanoma cells, suppressing their susceptibility to ferroptosis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-6073  0.349
2019 Porter RL, Magnus NKC, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A, Golczer G, Guo H, Yamada T, Kurokawa T, Yashaswini C, ... ... Haber DA, et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31843922 DOI: 10.1073/Pnas.1914915116  0.571
2019 Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, Zhong J, Rangachari D, Barbie DA, Phat S, Myers DT, Morris R, Kem M, Dubash TD, Kennedy EA, ... ... Haber DA, et al. Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. Cancer Discovery. PMID 31416802 DOI: 10.1158/2159-8290.Cd-19-0582  0.602
2019 Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, ... ... Haber DA, et al. Blood-based monitoring identifies acquired and targetable driver mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology. 3: 18. PMID 31341951 DOI: 10.1038/s41698-019-0090-5  0.562
2019 Tajima K, Matsuda S, Yae T, Drapkin BJ, Morris R, Boukhali M, Niederhoffer K, Comaills V, Dubash T, Nieman L, Guo H, Magnus NKC, Dyson N, Shioda T, Haas W, ... Haber DA, et al. SETD1A protects from senescence through regulation of the mitotic gene expression program. Nature Communications. 10: 2854. PMID 31253781 DOI: 10.1038/S41467-019-10786-W  0.443
2019 Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, ... ... Haber DA, et al. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell. PMID 31155233 DOI: 10.1016/J.Cell.2019.05.012  0.669
2019 Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, ... ... Haber DA, et al. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell. PMID 31031007 DOI: 10.1016/J.Cell.2019.04.004  0.396
2019 Onozato ML, Yapp C, Richardson D, Sundaresan T, Chahal V, Lee J, Sullivan JP, Madden MW, Shim HS, Liebers M, Ho Q, Maheswaran S, Haber DA, Zheng Z, Clancy B, et al. Highly Multiplexed FISH for in Situ Genomics. The Journal of Molecular Diagnostics : Jmd. PMID 30862547 DOI: 10.1016/J.Jmoldx.2019.01.010  0.408
2019 Zheng Y, Comaills V, Burr R, Boulay G, Miyamoto DT, Wittner BS, Emmons E, Sil S, Koulopoulos MW, Broderick KT, Tai E, Rengarajan S, Kulkarni AS, Shioda T, Wu CL, ... ... Haber DA, et al. COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. PMID 30819896 DOI: 10.1073/Pnas.1819303116  0.712
2019 Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, et al. Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. European Journal of Human Genetics : Ejhg. PMID 30718883 DOI: 10.1038/S41431-019-0346-0  0.415
2019 Hwang W, Pleskow H, Czapla JAA, Fisher R, Kamran S, Lee R, Saylor P, Zietman A, Silvia B, Ting D, Maheswaran S, Haber D, Efstathiou J, Miyamoto D. Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer International Journal of Radiation Oncology*Biology*Physics. 105: E663. DOI: 10.1016/J.Ijrobp.2019.06.1060  0.681
2018 Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, ... ... Haber DA, et al. A digital RNA signature of Circulating Tumor Cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discovery. PMID 30104333 DOI: 10.1158/2159-8290.Cd-18-0432  0.686
2018 Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, Phat S, Myers DT, Zhong J, Igo P, Hazar-Rethinam MH, LiCausi JA, Gomez-Caraballo M, Kem M, Jani KN, ... ... Haber DA, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Discovery. PMID 29483136 DOI: 10.1158/2159-8290.Cd-17-0935  0.455
2018 Sandlin RD, Wong KHK, Tessier SN, Swei A, Bookstaver LD, Ahearn BE, Maheswaran S, Haber DA, Stott SL, Toner M. Ultra-fast vitrification of patient-derived circulating tumor cell lines. Plos One. 13: e0192734. PMID 29474365 DOI: 10.1371/Journal.Pone.0192734  0.435
2018 Kalinich M, Haber DA. Cancer detection: Seeking signals in blood. Science (New York, N.Y.). 359: 866-867. PMID 29472467 DOI: 10.1126/Science.Aas9102  0.4
2018 Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, MacKenzie O, Shioda T, Sgroi D, Kapur R, ... ... Haber DA, et al. AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Molecular Cancer Research : McR. PMID 29453314 DOI: 10.1158/1541-7786.Mcr-17-0480  0.382
2018 Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, ... ... Haber DA, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29453278 DOI: 10.1073/Pnas.1719264115  0.749
2018 Miyamoto DT, Lee RJ, Kalinich M, LiCausi J, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, ... ... Haber DA, et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discovery. PMID 29301747 DOI: 10.1158/2159-8290.Cd-16-1406  0.676
2018 Richon V, Fisher DE, Letai A, Haber DA, Bardia A, Stott S, Yeku O, Sullivan R, Liu D, Spring L, Dagogo‐Jack I, Nagayama A, Franses J. Chabner Colloquium: Answering the Big Questions in Cancer Research & 2018 STO Annual Meeting Oncologist. 23. DOI: 10.1634/Theoncologist.2018-Ma-1  0.318
2018 Farago AF, Drapkin BJ, Charles A, Yeap BY, Heist RS, Azzoli CG, Jackman DM, Marcoux JP, Barbie DA, Myers DT, Phat S, Zhong J, Grinnell JB, Sequist LV, Mino-Kenudson M, ... ... Haber DA, et al. Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC). Journal of Clinical Oncology. 36: 8571-8571. DOI: 10.1200/Jco.2018.36.15_Suppl.8571  0.333
2018 Hong X, Sullivan RJ, Kalinich M, Kwan T, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence D, Flaherty KT, Sequist LV, ... ... Haber DA, et al. Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-144  0.692
2018 Drapkin BJ, George J, Stanzione M, Yeap BY, Mino-Kenudson M, Christensen CL, Dries R, Phat S, Zhong J, Myers DT, Licausi JA, Sundaresan T, Kem M, Abedpour N, Sequist LV, ... ... Haber DA, et al. Abstract 2972: Co-clinical trial of olaparib and temozolomide in SCLC PDX models uncovers new biomarkers of sensitivity Cancer Research. 78: 2972-2972. DOI: 10.1158/1538-7445.Am2018-2972  0.358
2018 Ligorio M, Sil S, Malagon-Lopez J, Misale S, Karabacak M, Nieman L, Maheswaran S, Haber DA, Warshaw AL, Castillo CF, Ferrone CR, Haas W, Aryee M, Ting DT. Abstract 210: Uncovering a novel layer of complexity in the architecture of pancreatic cancer Cancer Research. 78: 210-210. DOI: 10.1158/1538-7445.Am2018-210  0.495
2018 Haber DA. Abstract CN08-02: Molecular detection and characterization of circulating tumor cells Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Cn08-02  0.52
2018 Miyamoto D, Fisher R, Pleskow H, Milner J, Kalinich M, Potter S, Quilty J, Toner M, Maheswaran S, Haber D, Zietman A, Efstathiou J. Prospective Evaluation of a Digital RNA Circulating Tumor Cell Signature in Localized Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e173-e174. DOI: 10.1016/J.Ijrobp.2018.07.648  0.683
2017 Au SH, Edd J, Haber DA, Maheswaran S, Stott SL, Toner M. Clusters of Circulating Tumor Cells: a Biophysical and Technological Perspective. Current Opinion in Biomedical Engineering. 3: 13-19. PMID 29226271 DOI: 10.1016/J.Cobme.2017.08.001  0.4
2017 Wong KHK, Tessier SN, Miyamoto DT, Miller KL, Bookstaver LD, Carey TR, Stannard CJ, Thapar V, Tai EC, Vo KD, Emmons ES, Pleskow HM, Sandlin RD, Sequist LV, Ting DT, ... Haber DA, et al. Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nature Communications. 8: 1733. PMID 29170510 DOI: 10.1038/S41467-017-01705-Y  0.694
2017 Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes & Development. 31: 1827-1840. PMID 29051388 DOI: 10.1101/Gad.305805.117  0.448
2017 Jiang X, Wong KHK, Khankhel AH, Zeinali M, Reategui E, Phillips MJ, Luo X, Aceto N, Fachin F, Hoang AN, Kim W, Jensen AE, Sequist LV, Maheswaran S, Haber DA, et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab On a Chip. PMID 28932842 DOI: 10.1039/C7Lc00654C  0.413
2017 Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, Karabacak M, Pai V, Yu M, Smith K, Hwang H, Yang J, Shah S, Yarmush R, Sequist LV, ... ... Haber DA, et al. Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Scientific Reports. 7: 10936. PMID 28883519 DOI: 10.1038/S41598-017-11119-X  0.435
2017 Franses JW, Basar O, Kadayifci A, Yuksel O, Choz M, Kulkarni AS, Tai E, Vo KD, Arora KS, Desai N, Licausi JA, Toner M, Maheswaran S, Haber DA, Ryan DP, et al. Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. The Oncologist. PMID 28860411 DOI: 10.1634/Theoncologist.2017-0234  0.389
2017 Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, ... ... Haber DA, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nature Genetics. PMID 28825726 DOI: 10.1038/Ng.3934  0.597
2017 Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, ... ... Haber DA, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. PMID 28678785 DOI: 10.1038/Nature23007  0.376
2017 Au SH, Edd J, Stoddard AE, Wong KHK, Fachin F, Maheswaran S, Haber DA, Stott SL, Kapur R, Toner M. Microfluidic Isolation of Circulating Tumor Cell Clusters by Size and Asymmetry. Scientific Reports. 7: 2433. PMID 28550299 DOI: 10.1038/S41598-017-01150-3  0.311
2017 Micalizzi DS, Haber DA, Maheswaran S. Cancer metastasis through the prism of epithelial to mesenchymal transition in circulating tumor cells. Molecular Oncology. PMID 28544498 DOI: 10.1002/1878-0261.12081  0.474
2017 Miyamoto DT, Ting DT, Toner M, Maheswaran S, Haber DA. Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harbor Symposia On Quantitative Biology. PMID 28389596 DOI: 10.1101/Sqb.2016.81.031120  0.702
2017 Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes & Development. PMID 28242626 DOI: 10.1101/Gad.290957.116  0.364
2017 Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, Yu M, Karabacak NM, Comaills V, Morris R, Desai R, Desai N, Emmons E, Milner JD, Lee RJ, ... ... Haber DA, et al. Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications. 8: 14344. PMID 28181495 DOI: 10.1038/Ncomms14344  0.681
2017 Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, ... ... Haber DA, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 28096363 DOI: 10.1073/Pnas.1617032114  0.657
2017 Maheswaran S, Kalinich M, Bhan I, Miyamoto D, Zheng Y, Hong X, Kwan TT, Kapur R, Sequist L, Sullivan R, Bardia A, Lee R, Ting D, Toner M, Haber DA. Abstract SY24-01: High-throughput CTC detection for noninvasive cancer monitoring Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy24-01  0.724
2017 Farago AF, Drapkin BJ, Charles A, Yeap B, Heist RS, Azzoli CG, Jackman DM, Barbie DA, Choy E, Sequist LV, Maheswaran S, Haber DA, Hata AN, Dyson N, Shaw AT. Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct048  0.316
2017 Karabacak NM, Zheng Y, Emmons E, Koulopoulos M, Haber DA, Toner M, Maheswaran S. Abstract 4953: Single cell signaling analysis reveals circulating tumor cell markers of drug susceptibility and tumor heterogeneity Cancer Research. 77: 4953-4953. DOI: 10.1158/1538-7445.Am2017-4953  0.479
2017 Kwan TT, Bardia A, Sundaresan T, Spring L, Kalinich M, Miyamoto D, Hong X, LiCausi J, Ho U, Javaid S, Silva E, Sequist L, Maheswaran S, Haber D. Abstract 1736: A novel RNA-based assay for the detection and monitoring of circulating tumor cell signatures in breast cancer Cancer Research. 77: 1736-1736. DOI: 10.1158/1538-7445.Am2017-1736  0.716
2017 Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Kapur R, Muzikansky A, Zhang H, Weitz DA, ... ... Haber DA, et al. Abstract 1734: Absolute quantification of circulating tumor cell RNA enables high specificity detection of hepatocellular carcinoma Cancer Research. 77: 1734-1734. DOI: 10.1158/1538-7445.Am2017-1734  0.672
2017 Comaills V, Kabeche L, Morris R, Yu M, Madden MW, LiCausi JA, Aceto N, Zheng Y, Miyamoto DT, Ramaswamy S, Zou L, Haber DA, Maheswaran S. Abstract 1410: Proliferation during epithelial-to-mesenchymal transition induces genomic instability Cancer Research. 77: 1410-1410. DOI: 10.1158/1538-7445.Am2017-1410  0.587
2016 Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, Aceto N, Sil S, Zheng Y, Sundaresan T, Yae T, ... ... Haber DA, et al. Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Reports. 17: 2632-2647. PMID 27926867 DOI: 10.1016/J.Celrep.2016.11.022  0.702
2016 Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, ... ... Haber DA, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. PMID 27556950 DOI: 10.1038/Nature19328  0.412
2016 Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, ... ... Haber DA, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. PMID 27397505 DOI: 10.1016/J.Cell.2016.06.017  0.447
2016 Au SH, Storey BD, Moore JC, Tang Q, Chen YL, Javaid S, Sarioglu AF, Sullivan R, Madden MW, O'Keefe R, Haber DA, Maheswaran S, Langenau DM, Stott SL, Toner M. Clusters of circulating tumor cells traverse capillary-sized vessels. Proceedings of the National Academy of Sciences of the United States of America. PMID 27091969 DOI: 10.1073/Pnas.1524448113  0.324
2016 Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, et al. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials. 93: 71-82. PMID 27082874 DOI: 10.1016/J.Biomaterials.2016.03.044  0.417
2016 Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Brannigan BW, Arora KS, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu C, Shioda T, ... ... Haber DA, et al. Abstract IA09: Single cell RNA-sequencing of circulating tumor cells Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pmsclingen15-Ia09  0.725
2016 Connelly M, Chianese D, Morano C, Bui T, Powell S, Ngoubilly N, Sanders R, Barber T, Kapur R, Maheswaran S, Toner M, Haber D. Abstract 4955: Isolation and characterization of circulating tumor cells (CTCs) in breast and prostate cancer: Comparison of Harpoon CTC assay performance with the CellSearch CTC Test Cancer Research. 76: 4955-4955. DOI: 10.1158/1538-7445.Am2016-4955  0.44
2016 Zheng Y, Miyamoto DT, Wittner BS, Sullivan JP, Aceto N, Jordan NV, Yu M, Karabacak NM, Comaills V, Morris R, Desai R, Desai N, Emmons E, Lee RJ, Wu C, ... ... Haber DA, et al. Abstract 2679: Induction of β-globin protects circulating tumor cells from oxidative stress during dissemination Cancer Research. 76: 2679-2679. DOI: 10.1158/1538-7445.Am2016-2679  0.715
2016 Chianese D, Connelly M, Morano C, Bui T, Gross S, Sanders R, Barber T, Kapur R, Maheswaran S, Toner M, Haber D. Abstract 2422: Isolation of canonical and non-canonical circulating tumor cells (CTCs) by negative depletion using the Harpoon CTC Isolator and Chip Cancer Research. 76: 2422-2422. DOI: 10.1158/1538-7445.Am2016-2422  0.41
2015 Aceto N, Toner M, Maheswaran S, Haber DA. En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. Trends in Cancer. 1: 44-52. PMID 28741562 DOI: 10.1016/J.Trecan.2015.07.006  0.444
2015 Sundaresan TK, Haber DA. Fantastic voyage: the future of cancer diagnostics. The Lancet. Oncology. 16: 1596-8. PMID 26678190 DOI: 10.1016/S1470-2045(15)00469-6  0.36
2015 Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, ... ... Haber DA, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nature Chemical Biology. PMID 26656090 DOI: 10.1038/Nchembio.1986  0.416
2015 Bersani F, Lee E, Kharchenko PV, Xu AW, Liu M, Xega K, MacKenzie OC, Brannigan BW, Wittner BS, Jung H, Ramaswamy S, Park PJ, Maheswaran S, Ting DT, Haber DA. Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 26575630 DOI: 10.1073/Pnas.1518008112  0.402
2015 Stransky N, Ghandi M, Kryukov GV, Garraway LA, Lehár J, Liu M, Sonkin D, Kauffmann A, Venkatesan K, Edelman EJ, Riester M, Barretina J, Caponigro G, Schlegel R, Sellers WR, ... ... Haber DA, et al. Pharmacogenomic agreement between two cancer cell line data sets Nature. 528: 84-87. PMID 26570998 DOI: 10.1038/Nature15736  0.387
2015 Maheswaran S, Haber DA. Cell fate: Transition loses its invasive edge. Nature. 527: 452-3. PMID 26560026 DOI: 10.1038/Nature16313  0.39
2015 Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, et al. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. Plos One. 10: e0140310. PMID 26461489 DOI: 10.1371/Journal.Pone.0140310  0.364
2015 Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Janne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu H, ... ... Haber DA, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446944 DOI: 10.1158/1078-0432.Ccr-15-1031  0.339
2015 Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R, Wittner BS, Liu M, Engstrom A, Takahashi F, Black JC, Ramaswamy S, Shioda T, Hammell M, Haber DA, et al. SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nature Communications. 6: 8257. PMID 26394836 DOI: 10.1038/Ncomms9257  0.358
2015 Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, ... ... Haber DA, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (New York, N.Y.). 349: 1351-6. PMID 26383955 DOI: 10.1126/Science.Aab0917  0.688
2015 Sundaresan TK, Haber DA. Does molecular monitoring matter in early-stage breast cancer? Science Translational Medicine. 7: 302fs35. PMID 26311727 DOI: 10.1126/Scitranslmed.Aac9445  0.369
2015 Li W, Reátegui E, Park MH, Castleberry S, Deng JZ, Hsu B, Mayner S, Jensen AE, Sequist LV, Maheswaran S, Haber DA, Toner M, Stott SL, Hammond PT. Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. Biomaterials. 65: 93-102. PMID 26142780 DOI: 10.1016/J.Biomaterials.2015.06.036  0.419
2015 Kojić N, Milošević M, Petrović D, Isailović V, Sarioglu AF, Haber DA, Kojić M, Toner M. A computational study of circulating large tumor cells traversing microvessels. Computers in Biology and Medicine. 63: 187-95. PMID 26093786 DOI: 10.1016/J.Compbiomed.2015.05.024  0.346
2015 Maheswaran S, Haber DA. Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. Cancer Research. 75: 2411-5. PMID 25998619 DOI: 10.1158/0008-5472.Can-15-0145  0.478
2015 Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, ... ... Haber DA, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nature Methods. 12: 685-91. PMID 25984697 DOI: 10.1038/Nmeth.3404  0.642
2015 Kim WJ, Wittner BS, Amzallag A, Brannigan BW, Ting DT, Ramaswamy S, Maheswaran S, Haber DA. The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28. The Journal of Biological Chemistry. 290: 14381-90. PMID 25882849 DOI: 10.1074/Jbc.M114.631945  0.367
2015 Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife. 4. PMID 25686219 DOI: 10.7554/Elife.06132  0.408
2015 Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, Schott BJ, Ting DT, Stott SL, Toner M, Maheswaran S, ... ... Haber DA, et al. MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Molecular Cancer Research : McR. 13: 934-43. PMID 25678598 DOI: 10.1158/1541-7786.Mcr-14-0604  0.458
2015 Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, et al. Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Advanced Materials (Deerfield Beach, Fla.). 27: 1593-9. PMID 25640006 DOI: 10.1002/Adma.201404677  0.365
2015 Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (New York, N.Y.). 347: 273-7. PMID 25593184 DOI: 10.1126/Science.1257216  0.419
2015 Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA. Author response: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways Elife. DOI: 10.7554/Elife.06132.048  0.36
2015 Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, ... ... Haber DA, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters Nature Methods. 12: 685-691. DOI: 10.1038/nmeth.3404  0.598
2015 Aceto N, Toner M, Maheswaran S, Haber DA. En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition Trends in Cancer. 1: 44-52. DOI: 10.1016/j.trecan.2015.07.006  0.334
2015 Miyamoto D, Zheng Y, Wittner B, Lee R, Zhu H, Broderick K, Desai R, Brannigan B, Arora K, Dahl D, Sequist L, Smith M, Kapur R, Wu C, Shioda T, ... ... Haber D, et al. Single Cell RNA Profiling of Circulating Tumor Cells in Patients With Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 93: S104. DOI: 10.1016/J.Ijrobp.2015.07.250  0.7
2014 Bersani F, Lee J, Yu M, Morris R, Desai R, Ramaswamy S, Toner M, Haber DA, Parekkadan B. Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Research. 74: 7229-38. PMID 25339351 DOI: 10.1158/0008-5472.Can-14-1809  0.476
2014 Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, ... ... Haber DA, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Reports. 8: 1905-18. PMID 25242334 DOI: 10.1016/J.Celrep.2014.08.029  0.727
2014 Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, ... ... Haber DA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158: 1110-22. PMID 25171411 DOI: 10.1016/J.Cell.2014.07.013  0.689
2014 Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, ... ... Haber DA, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discovery. 4: 1299-309. PMID 25139148 DOI: 10.1158/2159-8290.Cd-14-0471  0.435
2014 Wong IY, Javaid S, Wong EA, Perk S, Haber DA, Toner M, Irimia D. Collective and individual migration following the epithelial-mesenchymal transition. Nature Materials. 13: 1063-71. PMID 25129619 DOI: 10.1038/Nmat4062  0.36
2014 Bardia A, Haber DA. Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3470-1. PMID 25024075 DOI: 10.1200/Jco.2014.57.1505  0.431
2014 Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, ... ... Haber DA, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (New York, N.Y.). 345: 216-20. PMID 25013076 DOI: 10.1126/Science.1253533  0.463
2014 Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, ... ... Haber DA, et al. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 24982446 DOI: 10.1200/Jco.2013.50.0272  0.322
2014 Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discovery. 4: 650-61. PMID 24801577 DOI: 10.1158/2159-8290.Cd-13-1014  0.473
2014 Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, ... ... Haber DA, et al. Isolation and molecular characterization of circulating melanoma cells. Cell Reports. 7: 645-53. PMID 24746818 DOI: 10.1016/J.Celrep.2014.03.039  0.406
2014 Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, ... ... Haber DA, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nature Protocols. 9: 694-710. PMID 24577360 DOI: 10.1038/Nprot.2014.044  0.392
2014 Burger A, Vasilyev A, Tomar R, Selig MK, Nielsen GP, Peterson RT, Drummond IA, Haber DA. A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Disease Models & Mechanisms. 7: 907-13. PMID 24311731 DOI: 10.1242/Dmm.013128  0.43
2014 Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, ... ... Haber DA, et al. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes, Chromosomes & Cancer. 53: 67-77. PMID 24249259 DOI: 10.1002/Gcc.22118  0.434
2014 Nahed BV, Sullivan JP, Madden MW, Oliveira SM, Chi AS, Springer S, Wakimoto H, Bhere D, Shah A, Spuhler P, Batchelor T, Louis DN, Toner M, Maheswaran S, Haber DA. American Brain Tumor Association Young Investigator Award 198 Circulating Tumor Cells in Patients With Glioblastoma Neurosurgery. 61: 226. DOI: 10.1227/01.Neu.0000452472.28571.08  0.376
2014 Ting DT, Wittner BS, Shah AM, Miyamoto DT, Brannigan BW, Xega K, Ciciliano J, MacKenzie OC, Trautwein J, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Kapur R, ... ... Haber DA, et al. Abstract NG04: Diversity of circulating tumor cells in a mouse pancreatic cancer model identified by single cell RNA sequencing Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ng04  0.73
2014 Aceto N, Bardia A, Spencer JA, Wittner BS, Yu M, Donaldson MC, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, ... ... Haber DA, et al. Abstract LB-192: Circulating tumor cell clusters are precursors of breast cancer metastasis Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-192  0.456
2014 Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, Stott SL, Ting DT, Ramaswamy S, Toner M, ... ... Haber DA, et al. Abstract 4832: Isolation and molecular characterization of circulating melanoma cells Cancer Research. 74: 4832-4832. DOI: 10.1158/1538-7445.Am2014-4832  0.429
2014 Rothenberg SM, Concannon K, Cullen S, Turke AB, Faber AC, Engelman JA, Maheswaran S, Haber DA. Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways Cancer Research. 74: 4773-4773. DOI: 10.1158/1538-7445.Am2014-4773  0.426
2014 Ligorio M, Indolfi L, Ting DT, Xega K, Aceto N, Bersani F, Ferrone CR, Haber DA, Langer R, Edelman ER, Clark JW. Abstract 4584: A novel drug-eluting platform for localized treatment of pancreatic cancer Cancer Research. 74: 4584-4584. DOI: 10.1158/1538-7445.Am2014-4584  0.378
2014 Sullivan JP, Nahed BV, Chi AS, Madden MN, Oliveira SM, Springer S, Wakimoto H, Bhere D, Shah K, Spuhler P, Shah AM, Louis DN, Toner M, Maheswaran S, Haber DA. Abstract 4004: Molecular characterization of circulating glioblastoma cells identifies a mesenchymal-like tumor cell subpopulation Cancer Research. 74: 4004-4004. DOI: 10.1158/1538-7445.Am2014-4004  0.492
2013 Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, Ting DT, Smolen GA, Zubrowski M, Desai R, Maheswaran S, Ramaswamy S, Whetstine JR, Haber DA. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Reports. 5: 1679-89. PMID 24360956 DOI: 10.1016/J.Celrep.2013.11.034  0.346
2013 Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, ... Haber DA, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98. PMID 23903755 DOI: 10.1126/Scitranslmed.3005753  0.327
2013 Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3088-94. PMID 23553848 DOI: 10.1158/1078-0432.Ccr-13-0319  0.622
2013 Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, ... ... Haber DA, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Science Translational Medicine. 5: 179ra47. PMID 23552373 DOI: 10.1126/Scitranslmed.3005616  0.72
2013 Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, ... ... Haber DA, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (New York, N.Y.). 339: 580-4. PMID 23372014 DOI: 10.1126/Science.1228522  0.486
2013 Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 41: D955-61. PMID 23180760 DOI: 10.1093/Nar/Gks1111  0.377
2013 Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D, Isakoff S, Ciciliano J, Wells M, Shah A, Concannon K, Donaldson M, Sequist L, Brachtel E, Sgroi D, ... ... Haber D, et al. Abstract A75: Circulating tumor cells in human breast cancer exhibit dynamic changes in epithelial and mesenchymal composition Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A75  0.49
2013 Haber DA, Yu M, Ozkumar E, Ting D, Miyamoto D, Lee R, Shah A, Bardia A, Stott S, Toner M, Maheswaran S. Abstract SY30-01: Molecular characterization of single circulating tumor cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy30-01  0.731
2013 Choy E, Butrynski J, Harmon D, Morgan J, George S, Wagner A, D'Adamo D, Cote G, Rubinstein Y, Benes C, Haber D, Baselga J, Demetri G. Abstract LB-174: Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-174  0.32
2013 Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Winokur D, Piris A, Nazarian RM, Brown RD, Godfrey JT, Mino-Kenudson M, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. Cancer Research. 73: 4568-4568. DOI: 10.1158/1538-7445.Am2013-4568  0.399
2013 Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S, Sridhar R, Futreal PA, Haber D, Stratton M, Benes C, McDermott U, Garnett M. Abstract 2206: Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Cancer Research. 73: 2206-2206. DOI: 10.1158/1538-7445.Am2013-2206  0.408
2013 Haber DA, Maheswaran S, Sequist L, Yu M, Ozkumur E, Ting D, Miyamoto D, Lee R, Shah A, Bardia A, Stott S, Toner M. Abstract PL06-04: Molecular characterization of circulating tumor cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pl06-04  0.727
2013 Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, ... Haber DA, et al. Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C137  0.409
2013 Jimenez R, Trautwein J, Efstathiou J, Mitin T, Maheswaran S, Haber D, Shipley W, Zietman A, Wu C, Miyamoto D. Feasibility of Gene Expression Signature Analysis in Prostate Cancer Biopsy Specimens to Predict Outcomes Following Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 87: S669. DOI: 10.1016/J.Ijrobp.2013.06.1774  0.64
2012 Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, ... ... Haber DA, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery. 2: 995-1003. PMID 23093251 DOI: 10.1158/2159-8290.Cd-12-0222  0.667
2012 Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, ... ... Haber DA, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 487: 510-3. PMID 22763454 DOI: 10.1038/Nature11217  0.458
2012 Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, ... ... Haber DA, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005  0.456
2012 Shah AM, Yu M, Nakamura Z, Ciciliano J, Ulman M, Kotz K, Stott SL, Maheswaran S, Haber DA, Toner M. Biopolymer system for cell recovery from microfluidic cell capture devices. Analytical Chemistry. 84: 3682-8. PMID 22414137 DOI: 10.1021/Ac300190J  0.38
2012 Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 148: 639-50. PMID 22341439 DOI: 10.1016/J.Cell.2011.12.033  0.448
2012 Kim WJ, Rivera MN, Coffman EJ, Haber DA. The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Molecular Cell. 45: 587-97. PMID 22285752 DOI: 10.1016/J.Molcel.2011.12.025  0.313
2012 Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel E, Vivanco MD, Haber DA, Zou L, Maheswaran S. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proceedings of the National Academy of Sciences of the United States of America. 109: 2760-5. PMID 21930940 DOI: 10.1073/Pnas.1018867108  0.364
2012 Lee RJ, Michaelson MD, Saylor PJ, Gurski CA, Rothenberg SM, Miyamoto DT, Maheswaran S, Haber DA, Goldin JG, Smith MR. Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. Journal of Clinical Oncology. 30: 4566-4566. DOI: 10.1200/Jco.2012.30.15_Suppl.4566  0.584
2012 Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J. Abstract LB-427: TAK1 (MAP3K7) inhibition promotes apoptosis in KRAS dependent colon cancers Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-427  0.445
2012 Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Gilman AJ, Ulman MJ, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, ... ... Haber DA, et al. Abstract 5304: RNA sequencing of circulating tumor cells implicates WNT signaling in pancreatic cancer metastasis Cancer Research. 72: 5304-5304. DOI: 10.1158/1538-7445.Am2012-5304  0.485
2012 Rothenberg SM, Wargo J, Juric D, Corcoran RB, Winokur D, Flaherty KT, Baselga J, Maheswaran S, Engelman JA, Haber DA. Abstract 2446: Real-time molecular imaging of targeted therapies in patient-derived tumor cells by quantitative immunofluorescence microscopy Cancer Research. 72: 2446-2446. DOI: 10.1158/1538-7445.Am2012-2446  0.468
2012 Tao J, Ip P, Auricchio N, Juric D, Yu M, Shyamala M, Kim P, Singh S, Hazra S, Haber D, Scaltriti M, Baselga J. Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S5-7  0.395
2012 Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D, Isakoff S, Ciciliano J, Wells M, Shah A, Concannon K, Sequist L, Brachtel E, Sgroi D, Baselga J, ... ... Haber D, et al. Abstract P2-01-14: circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-01-14  0.496
2012 Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, ... ... Haber DA, et al. Erratum: Corrigendum: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis Nature. 490: 570-570. DOI: 10.1038/Nature11644  0.302
2011 Yee AJ, Raz T, Amzallag A, Lipson D, Giladi E, Lopez H, Borger DR, Mino-Kenudson M, Thompson JF, Iafrate AJ, Milos P, Haber DA, Ramaswamy S. Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue derived from patients with lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10550. PMID 28021919 DOI: 10.1200/Jco.2011.29.15_Suppl.10550  0.341
2011 Lennerz JK, Kwak EL, Michael M, Fox SB, Ackerman A, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang Y, Clark JW, Solomon BJ, Iafrate AJ. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4130. PMID 28021188 DOI: 10.1200/Jco.2011.29.15_Suppl.4130  0.409
2011 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/Jco.2011.35.4928  0.408
2011 Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, Kim WJ, Kronenberg HM, Baron R, Haber DA, Bardeesy N. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Developmental Cell. 20: 583-96. PMID 21571217 DOI: 10.1016/J.Devcel.2011.03.013  0.393
2011 Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell. 145: 19-24. PMID 21458664 DOI: 10.1016/J.Cell.2011.03.026  0.383
2011 Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. The Journal of Cell Biology. 192: 373-82. PMID 21300848 DOI: 10.1083/Jcb.201010021  0.42
2011 Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (New York, N.Y.). 331: 593-6. PMID 21233348 DOI: 10.1126/Science.1200801  0.423
2011 Mitra D, Luo X, Haber DA, Fisher DE. Abstract PR6: Why redheads are at increased risk of melanoma: A novel BRAF mutant mouse model Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-Pr6  0.372
2011 Akhavanfard S, Rivera MN, Dias-Santagata DC, Vargas SO, Pomeroy S, Haber DA, Iafrate AJ. Abstract 4349: The tumor suppressor WTX is inactivated in a subset of pediatric tumors Cancer Research. 71: 4349-4349. DOI: 10.1158/1538-7445.Am2011-4349  0.436
2011 Nagrath S, Moore AL, Zenali M, Chekaluk YI, Peters EM, Kwiatowski DJ, Haber DA, Henske EP, Toner M. Abstract 1571: Novel microfluidic technology and biology based approach for isolation and characterization of circulating cells from the peripheral blood of patients with Lymphangioleiomyomatosis Cancer Research. 71: 1571-1571. DOI: 10.1158/1538-7445.Am2011-1571  0.406
2011 Singh A, Sweeney MF, Settleman J, Haber DA. Abstract C155: Inhibition of TAK1 promotes apoptosis in KRAS and Wnt pathway codependent colon cancers. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C155  0.435
2011 Haber DA, Rivera MN. Pathogenesis of Wilms Tumor Annual Review of Pathology-Mechanisms of Disease. 7: 110301101326014. DOI: 10.1146/Annurev-Pathol-011110-130251  0.354
2010 Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber DA. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes & Development. 24: 2654-65. PMID 21062900 DOI: 10.1101/Gad.1989110  0.37
2010 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... ... Haber DA, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/Nejmoa1006448  0.402
2010 Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, ... ... Haber DA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proceedings of the National Academy of Sciences of the United States of America. 107: 18392-7. PMID 20930119 DOI: 10.1073/Pnas.1012539107  0.713
2010 Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber DA. Amplification-free digital gene expression profiling from minute cell quantities. Nature Methods. 7: 619-21. PMID 20639869 DOI: 10.1038/Nmeth.1480  0.353
2010 Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Molecular Cancer Research : McR. 8: 975-85. PMID 20571064 DOI: 10.1158/1541-7786.Mcr-10-0033  0.391
2010 Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BE. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 6: 591-602. PMID 20569696 DOI: 10.1016/J.Stem.2010.03.016  0.408
2010 Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, ... Haber DA, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Molecular Medicine. 2: 146-58. PMID 20432502 DOI: 10.1002/Emmm.201000070  0.409
2010 Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, ... ... Haber DA, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Science Translational Medicine. 2: 25ra23. PMID 20424012 DOI: 10.1126/scitranslmed.3000403  0.66
2010 Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews. Cancer. 10: 241-53. PMID 20300105 DOI: 10.1038/Nrc2820  0.382
2010 Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, ... ... Haber DA, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Research. 70: 2158-64. PMID 20215515 DOI: 10.1158/0008-5472.Can-09-3458  0.417
2010 Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Current Opinion in Genetics & Development. 20: 96-9. PMID 20071161 DOI: 10.1016/J.Gde.2009.12.002  0.484
2010 Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Cohen EEW, Louis DN, Settleman J, Haber DA. Abstract 5757: A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers Cancer Research. 70: 5757-5757. DOI: 10.1158/1538-7445.Am10-5757  0.438
2010 Yee AJ, Wittner BS, Gentry J, Mahoney C, McCutcheon K, Singh A, Greninger P, Ma X, Erlander MG, Sharma SV, Haber DA, Shioda T, Settleman J, Ramaswamy S. Abstract 2203: Integrative analysis for efficient candidate oncogene discovery in cancer cell lines Cancer Research. 70: 2203-2203. DOI: 10.1158/1538-7445.Am10-2203  0.44
2010 Nagrath S, Stott SL, Lee RJ, Yu M, Ulkus LL, Iafrate JA, Smith MR, Tompkins RG, Sequist LV, Haber DA, Maheswaran S, Toner M. Abstract 1136: Detection and characterization of circulating tumor cells in localized and metastatic prostate cancer patients using CTC-Chip microfluidic technology Cancer Research. 70: 1136-1136. DOI: 10.1158/1538-7445.Am10-1136  0.455
2009 Lee RJ, Stott SL, Nagrath S, Ulkus LE, Dahl DM, Smith MR, Toner M, Maheswaran S, Haber DA. Analyses of circulating tumor cell (CTC) dynamics and treatment response in prostate cancer using the CTC-chip microfluidic device. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5149. PMID 27964441 DOI: 10.1200/Jco.2009.27.15_Suppl.5149  0.413
2009 Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology. 11: 1444-50. PMID 19935651 DOI: 10.1038/Ncb1993  0.397
2009 Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, et al. Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Molecular Cancer Research : McR. 7: 1510-6. PMID 19737971 DOI: 10.1158/1541-7786.Mcr-09-0033  0.438
2009 Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber DA. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes & Development. 23: 1737-42. PMID 19651985 DOI: 10.1101/Gad.1809309  0.4
2009 Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DA. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proceedings of the National Academy of Sciences of the United States of America. 106: 8338-43. PMID 19416806 DOI: 10.1073/Pnas.0811349106  0.389
2009 McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, ... Haber DA, et al. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Research. 69: 3937-46. PMID 19366796 DOI: 10.1158/0008-5472.Can-08-4327  0.475
2009 Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 281-3. PMID 19247082 DOI: 10.1097/Jto.0B013E3181989565  0.465
2009 Zhang J, Ji J, Yi M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. Abstract LB-228: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-228  0.405
2008 Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6867-76. PMID 18980981 DOI: 10.1158/1078-0432.Ccr-08-0093  0.351
2008 Kim S, Mohapatra G, Haber DA. In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. British Journal of Cancer. 99: 1302-6. PMID 18797466 DOI: 10.1038/Sj.Bjc.6604644  0.365
2008 Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J. Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America. 105: 12480-4. PMID 18711136 DOI: 10.1073/Pnas.0803217105  0.378
2008 Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, ... ... Haber DA, et al. Detection of mutations in EGFR in circulating lung-cancer cells. The New England Journal of Medicine. 359: 366-77. PMID 18596266 DOI: 10.1056/Nejmoa0800668  0.442
2008 Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DA. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4079-84. PMID 18593984 DOI: 10.1158/1078-0432.Ccr-07-5030  0.321
2008 Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber DA. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proceedings of the National Academy of Sciences of the United States of America. 105: 9284-9. PMID 18591665 DOI: 10.1073/Pnas.0800803105  0.368
2008 Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Research. 68: 4853-61. PMID 18559533 DOI: 10.1158/0008-5472.Can-07-6787  0.361
2008 Li H, Smolen GA, Beers LF, Xia L, Gerald W, Wang J, Haber DA, Lee SB. Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. Plos One. 3: e2353. PMID 18523561 DOI: 10.1371/Journal.Pone.0002353  0.39
2008 Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2988-93. PMID 18483364 DOI: 10.1158/1078-0432.Ccr-07-4723  0.365
2008 Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, ... ... Haber DA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2442-9. PMID 18458038 DOI: 10.1200/Jco.2007.14.8494  0.332
2008 McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Research. 68: 3389-95. PMID 18451166 DOI: 10.1158/0008-5472.Can-07-6186  0.434
2008 Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Molecular Cancer Therapeutics. 7: 874-9. PMID 18413800 DOI: 10.1158/1535-7163.Mct-07-2387  0.304
2008 Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Research. 68: 2789-94. PMID 18413746 DOI: 10.1158/0008-5472.Can-07-6205  0.387
2008 Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 111: 4716-22. PMID 18299447 DOI: 10.1182/Blood-2007-10-113068  0.449
2007 Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 450: 1235-9. PMID 18097410 DOI: 10.1038/Nature06385  0.448
2007 Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, ... ... Haber DA, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer. Journal International Du Cancer. 121: 2661-7. PMID 17721994 DOI: 10.1002/Ijc.23026  0.371
2007 Smolen GA, Schott BJ, Stewart RA, Diederichs S, Muir B, Provencher HL, Look AT, Sgroi DC, Peterson RT, Haber DA. A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. Genes & Development. 21: 2131-6. PMID 17704304 DOI: 10.1101/Gad.1561507  0.308
2007 Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Research. 67: 7319-26. PMID 17671201 DOI: 10.1158/0008-5472.Can-06-4625  0.317
2007 Han M, Rivera MN, Batten JM, Haber DA, Dal Cin P, Iafrate AJ. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes, Chromosomes & Cancer. 46: 909-13. PMID 17620295 DOI: 10.1002/Gcc.20476  0.364
2007 Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 446: 145-6. PMID 17344839 DOI: 10.1038/446145A  0.377
2007 Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib Cancer Research. 67: 2325-2330. PMID 17332364 DOI: 10.1158/0008-5472.Can-06-4293  0.318
2007 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews. Cancer. 7: 169-81. PMID 17318210 DOI: 10.1038/Nrc2088  0.379
2007 Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 587-95. PMID 17290067 DOI: 10.1200/Jco.2006.07.3585  0.35
2007 Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, ... Haber DA, et al. A recurrent mutation in PALB2 in Finnish cancer families Nature. 446: 316-319. PMID 17287723 DOI: 10.1038/Nature05609  0.394
2007 Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. The Oncologist. 12: 90-8. PMID 17285735 DOI: 10.1634/Theoncologist.12-1-90  0.337
2007 Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (New York, N.Y.). 315: 642-5. PMID 17204608 DOI: 10.1126/Science.1137509  0.405
2007 Bell DW, Haber DA. A blood-based test for epidermal growth factor receptor mutations in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3875-7. PMID 16818680 DOI: 10.1158/1078-0432.Ccr-06-0670  0.369
2006 Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 10: 425-35. PMID 17097564 DOI: 10.1016/J.Ccr.2006.09.014  0.355
2006 Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America. 103: 12405-10. PMID 16894141 DOI: 10.1073/Pnas.0605579103  0.403
2006 Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 419-26. PMID 16869779 DOI: 10.1101/Sqb.2005.70.043  0.35
2006 Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4403s-4408s. PMID 16857818 DOI: 10.1158/1078-0432.Ccr-06-0099  0.339
2006 Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4392s-4395s. PMID 16857816 DOI: 10.1158/1078-0432.Ccr-06-0096  0.39
2006 Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4365s-4371s. PMID 16857812 DOI: 10.1158/1078-0432.Ccr-06-1005  0.33
2006 Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, ... ... Haber DA, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4283-7. PMID 16857803 DOI: 10.1158/1078-0432.Ccr-06-0189  0.374
2006 Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3908-14. PMID 16818686 DOI: 10.1158/1078-0432.Ccr-06-0462  0.336
2006 Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, ... Haber DA, et al. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Research. 66: 3452-5. PMID 16585167 DOI: 10.1158/0008-5472.Can-05-4181  0.426
2006 Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Research. 66: 1923-8. PMID 16488990 DOI: 10.1158/0008-5472.Can-05-1237  0.409
2006 Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America. 103: 2316-21. PMID 16461907 DOI: 10.1073/Pnas.0508776103  0.465
2006 Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Seminars in Cancer Biology. 15: 197-205. PMID 15826834 DOI: 10.1016/J.Semcancer.2005.01.005  0.426
2005 Lynch TJ, Bell D, Haber D, Johnson D, Giaccone G, Fukuoka M, Kris M, Herbst R, Krebs A, Ochs J. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7006. PMID 27943795 DOI: 10.1200/Jco.2005.23.16_Suppl.7006  0.306
2005 Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8105-8. PMID 16299242 DOI: 10.1158/1078-0432.Ccr-05-0926  0.331
2005 Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics. 37: 1315-6. PMID 16258541 DOI: 10.1038/Ng1671  0.365
2005 Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, ... ... Haber DA, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8081-92. PMID 16204011 DOI: 10.1200/Jco.2005.02.7078  0.368
2005 Sequist LV, Haber DA, Lynch TJ. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5668-70. PMID 16115901 DOI: 10.1158/1078-0432.Ccr-05-1055  0.375
2005 Lorenzen JA, Bonacci BB, Palmer RE, Wells C, Zhang J, Haber DA, Goldstein AM, Mayer AN. Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expression Patterns : Gep. 6: 45-56. PMID 16027046 DOI: 10.1016/J.Modgep.2005.05.001  0.324
2005 Haber DA, Settleman J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle (Georgetown, Tex.). 4: 1057-9. PMID 15970680 DOI: 10.4161/Cc.4.8.1874  0.356
2005 Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecologic Oncology. 98: 124-8. PMID 15913747 DOI: 10.1016/J.Ygyno.2005.04.007  0.398
2005 Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, ... ... Haber DA, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America. 102: 7665-70. PMID 15897464 DOI: 10.1073/Pnas.0502860102  0.342
2005 Riemenschneider MJ, Bell DW, Haber DA, Louis DN. Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. The New England Journal of Medicine. 352: 1724-5. PMID 15843680 DOI: 10.1056/Nejm200504213521622  0.328
2005 Masciari S, Harris L, Branda K, Petkovska A, Paez J, Haber D, Digianni L, Sellers W, Li F, Garber J. Germline TP53 mutations in women with very early onset breast cancer (BR) Journal of Clinical Oncology. 23: 1015-1015. DOI: 10.1200/Jco.2005.23.16_Suppl.1015  0.31
2004 Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Research. 64: 7846-51. PMID 15520190 DOI: 10.1158/0008-5472.Can-04-1502  0.31
2004 Song YH, Mirey G, Betson M, Haber DA, Settleman J. The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Current Biology : Cb. 14: 1354-9. PMID 15296752 DOI: 10.1016/J.Cub.2004.06.064  0.311
2004 Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (New York, N.Y.). 305: 1163-7. PMID 15284455 DOI: 10.1126/Science.1101637  0.333
2004 Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, ... ... Haber DA, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 5: 607-16. PMID 15193263 DOI: 10.1016/J.Ccr.2004.05.015  0.398
2004 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine. 350: 2129-39. PMID 15118073 DOI: 10.1056/Nejmoa040938  0.396
2004 Haber DA. The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. Cell. 115: 507-8. PMID 14651841 DOI: 10.1016/S0092-8674(03)00933-4  0.33
2003 Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, Hsiao L, Jensen RV, Gullans SR, Haber DA. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1 Current Biology. 13: 1625-1629. PMID 13678594 DOI: 10.1016/J.Cub.2003.08.054  0.303
2003 Ryan PD, Haber DA, Shannon KM, Smith BL, Fan MJ. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. The New England Journal of Medicine. 349: 1076-82. PMID 12968092 DOI: 10.1056/Nejmcpc030018  0.306
2003 Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, Gerald WL, Haber DA. Identification of a DNA- binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein Genes and Development. 17: 2094-2107. PMID 12923058 DOI: 10.1101/Gad.1110703  0.425
2003 Varley J, Haber DA. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Research : Bcr. 5: 123-5. PMID 12793891 DOI: 10.1186/Bcr582  0.371
2003 Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 112: 673-84. PMID 12628187 DOI: 10.1016/S0092-8674(03)00155-7  0.44
2003 Paulding CA, Ruvolo M, Haber DA. The Tre2 (USP6) oncogene is a hominoid-specific gene. Proceedings of the National Academy of Sciences of the United States of America. 100: 2507-11. PMID 12604796 DOI: 10.1073/Pnas.0437015100  0.315
2002 Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber DA. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell. 2: 497-505. PMID 12498718 DOI: 10.1016/S1535-6108(02)00205-2  0.438
2002 Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 110: 467-78. PMID 12202036 DOI: 10.1016/S0092-8674(02)00824-3  0.394
2002 Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. The New England Journal of Medicine. 346: 1660-1662. PMID 12024000 DOI: 10.1056/Nejmed020044  0.398
2002 Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber DA. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene. 21: 2009-19. PMID 11960373 DOI: 10.1038/Sj.Onc.1205262  0.398
2001 Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Current Biology : Cb. 11: 1805-9. PMID 11719225 DOI: 10.1016/S0960-9822(01)00560-7  0.362
2001 Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. Journal of the National Cancer Institute. 93: 1698-703. PMID 11717330 DOI: 10.1093/Jnci/93.22.1698  0.389
2001 Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA, Johnston PG, Harkin DP. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. 20: 6123-31. PMID 11593420 DOI: 10.1038/Sj.Onc.1204712  0.379
2001 Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 413: 311-6. PMID 11565033 DOI: 10.1038/35095068  0.36
2001 Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DA. Cascades of transcriptional induction during human lymphocyte activation. European Journal of Cell Biology. 80: 321-8. PMID 11432721 DOI: 10.1078/0171-9335-00162  0.335
2001 Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 105: 149-60. PMID 11301010 DOI: 10.1016/S0092-8674(01)00304-X  0.345
2001 Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. The Embo Journal. 20: 1897-909. PMID 11296223 DOI: 10.1093/Emboj/20.8.1897  0.406
2001 Wang W, Lee SB, Palmer R, Ellisen LW, Haber DA. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. The Journal of Biological Chemistry. 276: 16810-6. PMID 11278547 DOI: 10.1074/Jbc.M009687200  0.354
2001 Lee SB, Haber DA. Wilms tumor and the WT1 gene. Experimental Cell Research. 264: 74-99. PMID 11237525 DOI: 10.1006/Excr.2000.5131  0.449
2001 Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KE. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene Blood. 97: 1131-1133. PMID 11159547 DOI: 10.1182/Blood.V97.4.1131  0.334
2000 Haber D. Roads leading to breast cancer. The New England Journal of Medicine. 343: 1566-8. PMID 11087889 DOI: 10.1056/Nejm200011233432111  0.422
2000 Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles Proceedings of the National Academy of Sciences of the United States of America. 97: 11451-11454. PMID 11027344 DOI: 10.1073/Pnas.97.21.11451  0.338
2000 Daniels GH, Haber DA. Will radioiodine be useful in treatment of breast cancer? Nature Medicine. 6: 859-60. PMID 10932214 DOI: 10.1038/78604  0.332
2000 Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes, Chromosomes & Cancer. 27: 124-9. PMID 10612799 DOI: 10.1002/(Sici)1098-2264(200002)27:2<124::Aid-Gcc2>3.0.Co;2-M  0.397
2000 Haber DA. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 3367-70. PMID 10550129 DOI: 10.1200/Jco.1999.17.11.3367  0.348
1999 Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (New York, N.Y.). 286: 2528-31. PMID 10617473 DOI: 10.1126/Science.286.5449.2528  0.434
1999 Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1259. PMID 10561187 DOI: 10.1200/Jco.1999.17.4.1259  0.396
1999 Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 98: 663-73. PMID 10490105 DOI: 10.1016/S0092-8674(00)80053-7  0.328
1999 Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 97: 575-86. PMID 10367887 DOI: 10.1016/S0092-8674(00)80769-2  0.356
1998 Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E, Buckler AJ, Wise C, Ashley J, Lovett M, Valentine MB, ... ... Haber DA, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proceedings of the National Academy of Sciences of the United States of America. 95: 13765-70. PMID 9811875 DOI: 10.1073/Pnas.95.23.13765  0.542
1998 FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DA. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 17: 727-31. PMID 9715274 DOI: 10.1038/Sj.Onc.1201984  0.379
1998 Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genetics. 19: 182-6. PMID 9620778 DOI: 10.1038/554  0.388
1998 Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 16: 2403-6. PMID 9620558 DOI: 10.1038/Sj.Onc.1201762  0.391
1998 Haber DA, Fearon ER. The promise of cancer genetics. Lancet (London, England). SII1-8. PMID 9606360 DOI: 10.1016/S0140-6736(98)90326-9  0.341
1998 Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber DA. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene. 16: 2041-50. PMID 9572485 DOI: 10.1038/Sj.Onc.1201741  0.354
1998 Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, Haber DA. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes & Development. 12: 1108-20. PMID 9553041 DOI: 10.1101/Gad.12.8.1108  0.328
1998 Nichols KE, Li FP, Haber DA, Diller L. Childhood cancer predisposition: applications of molecular testing and future implications. The Journal of Pediatrics. 132: 389-97. PMID 9544888 DOI: 10.1016/S0022-3476(98)70007-1  0.362
1998 Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 16: 1217-22. PMID 9528864 DOI: 10.1038/Sj.Onc.1201882  0.387
1998 Ellisen LW, Haber DA. Hereditary breast cancer. Annual Review of Medicine. 49: 425-36. PMID 9509273 DOI: 10.1146/ANNUREV.MED.49.1.425  0.313
1998 Shafman TD, Nixon AJ, Levitz S, Gibans L, Nichols KE, Bell D, Isselbacher KJ, Manola J, Gelman R, Garber J, Haber DA, Harris JR. Prevalence of ataxia-telangiectasia heterozygosity in patients developing contralateral breast cancer following treatment with conservative surgery and radiation therapy International Journal of Radiation Oncology*Biology*Physics. 42: 253. DOI: 10.1016/S0360-3016(98)80359-3  0.312
1997 Haber DA. Splicing into senescence: the curious case of p16 and p19ARF. Cell. 91: 555-8. PMID 9393847 DOI: 10.1016/S0092-8674(00)80441-9  0.369
1997 Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber DA. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nature Genetics. 17: 309-13. PMID 9354795 DOI: 10.1038/Ng1197-309  0.356
1997 Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90: 785-95. PMID 9288757 DOI: 10.1016/S0092-8674(00)80538-3  0.448
1997 Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. The New England Journal of Medicine. 336: 1416-21. PMID 9145678 DOI: 10.1056/Nejm199705153362003  0.351
1997 Ishioka C, Suzuki T, FitzGerald M, Krainer M, Shimodaira H, Shimada A, Nomizu T, Isselbacher KJ, Haber D, Kanamaru R. Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proceedings of the National Academy of Sciences of the United States of America. 94: 2449-53. PMID 9122215 DOI: 10.1073/Pnas.94.6.2449  0.363
1996 Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Molecular and Cellular Biology. 16: 6945-56. PMID 8943350 DOI: 10.1128/Mcb.16.12.6945  0.333
1996 Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, ... Haber DA, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families Nature Medicine. 2: 1179-1183. PMID 8898735 DOI: 10.1038/Nm1196-1179  0.338
1996 Haber DA, Englert C, Maheswaran S. Functional properties of WT1. Medical and Pediatric Oncology. 27: 453-5. PMID 8827073 DOI: 10.1002/(Sici)1096-911X(199611)27:5<453::Aid-Mpo11>3.0.Co;2-B  0.425
1996 FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proceedings of the National Academy of Sciences of the United States of America. 93: 8541-5. PMID 8710906 DOI: 10.1073/Pnas.93.16.8541  0.301
1996 FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, ... ... Haber DA, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. The New England Journal of Medicine. 334: 143-9. PMID 8531968 DOI: 10.1056/Nejm199601183340302  0.356
1995 Haber DA. Telomeres, cancer, and immortality. The New England Journal of Medicine. 332: 955-6. PMID 7877656 DOI: 10.1056/Nejm199504063321412  0.463
1995 Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes & Development. 9: 2143-56. PMID 7657166 DOI: 10.1101/Gad.9.17.2143  0.344
1995 Grundy P, Coppes MJ, Haber D. Molecular Genetics of Wilms Tumor Hematology/Oncology Clinics of North America. 9: 1201-1216. DOI: 10.1016/S0889-8588(18)30041-8  0.372
1995 Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DA. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. The Embo Journal. 14: 4662-4675. DOI: 10.1002/J.1460-2075.1995.Tb00148.X  0.392
1994 Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science (New York, N.Y.). 262: 2057-9. PMID 8266105 DOI: 10.1126/Science.8266105  0.426
1994 Coppes MJ, Haber DA, Grundy PE. Genetic events in the development of Wilms' tumor. The New England Journal of Medicine. 331: 586-90. PMID 8047084 DOI: 10.1056/Nejm199409013310906  0.342
1994 Weremowicz S, Kozakewich HP, Haber D, Park S, Morton CC, Fletcher JA. Identification of genetically aberrant cell lineages in Wilms' tumors Genes Chromosomes and Cancer. 10: 40-48. PMID 7519872 DOI: 10.1002/Gcc.2870100107  0.424
1993 Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, Griffin J, Minden M, Housman DE, Haber DA. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma Nature Genetics. 4: 415-420. PMID 8401592 DOI: 10.1038/ng0893-415  0.474
1993 Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, Haber DA. Physical and functional interaction between WT1 and p53 proteins Proceedings of the National Academy of Sciences of the United States of America. 90: 5100-5104. PMID 8389468 DOI: 10.1073/Pnas.90.11.5100  0.399
1993 Skare J, Wu B, Madan S, Pulijaal V, Purtilo D, Haber D, Nelson D, Sylla B, Grierson H, Nitowsky H, Glaser J, Wissink J, White B, Holden J, Housman D, et al. Characterization of three overlapping deletions causing X-linked lymphoproliferative disease Genomics. 16: 254-255. PMID 8387453 DOI: 10.1006/Geno.1993.1169  0.454
1993 Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, Haber DA. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour Nature Genetics. 5: 363-367. PMID 8298644 DOI: 10.1038/Ng1293-363  0.304
1992 Baird PN, Groves N, Haber DA, Housman DE, Cowell JK. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene. 7: 2141-9. PMID 1331933  0.466
1992 Haber DA, Housman DE. The genetics of Wilms' tumor. Advances in Cancer Research. 59: 41-68. PMID 1325734 DOI: 10.1016/S0065-230X(08)60302-4  0.576
1992 Haber DA, Housman DE. Role of the WT1 gene in Wilms' tumour. Cancer Surveys. 12: 105-17. PMID 1322241  0.466
1992 Haber DA, Timmers HT, Pelletier J, Sharp PA, Housman DE. A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. Proceedings of the National Academy of Sciences of the United States of America. 89: 6010-4. PMID 1321431 DOI: 10.1073/Pnas.89.13.6010  0.581
1991 Cowell JK, Wadey RB, Haber DA, Call KM, Housman DE, Pritchard J. Structural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene. 6: 595-9. PMID 1851548  0.44
1991 Buckler AJ, Chang DD, Graw SL, Brook JD, Haber DA, Sharp PA, Housman DE. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proceedings of the National Academy of Sciences of the United States of America. 88: 4005-9. PMID 1850845 DOI: 10.1073/Pnas.88.9.4005  0.5
1991 Haber DA, Housman DE. Rate-limiting steps: the genetics of pediatric cancers. Cell. 64: 5-8. PMID 1846091 DOI: 10.1016/0092-8674(91)90200-I  0.51
1991 Mannens M, Hoovers JMN, Bleeker-Wagemakers EM, Redeker E, Bliek J, Overbeeke-Melkert M, Saunders G, Williams B, van Heynigen V, Junien C, Haber D, Speleman F, Heyting C, Slater RM, Leschot NJ, et al. The distal region of 11p13 and associated genetic diseases Genomics. 11: 284-293. PMID 1769647 DOI: 10.1016/0888-7543(91)90134-Z  0.357
1991 Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong LC, Saunders GF. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. American Journal of Human Genetics. 48: 997-1003. PMID 1673293  0.521
1991 Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Molecular and Cellular Biology. 11: 1707-12. PMID 1671709 DOI: 10.1128/Mcb.11.3.1707  0.551
1991 Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proceedings of the National Academy of Sciences of the United States of America. 88: 9618-22. PMID 1658787 DOI: 10.1073/Pnas.88.21.9618  0.542
1991 Schwartz CE, Haber DA, Stanton VP, Strong LC, Skolnick MH, Housman DE. Familial predisposition to Wilms tumor does not segregate with the WT1 gene. Genomics. 10: 927-30. PMID 1655633 DOI: 10.1016/0888-7543(91)90181-D  0.532
1991 Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Fine RN, Silverman BL, Haber DA, Housman D. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 67: 437-447. PMID 1655284 DOI: 10.1016/0092-8674(91)90194-4  0.543
1991 Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature. 353: 431-4. PMID 1654525 DOI: 10.1038/353431A0  0.525
1991 Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes & Development. 5: 1345-56. PMID 1651275 DOI: 10.1101/Gad.5.8.1345  0.537
1990 Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 61: 1257-69. PMID 2163761 DOI: 10.1016/0092-8674(90)90690-G  0.561
1990 Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 60: 509-20. PMID 2154335 DOI: 10.1016/0092-8674(90)90601-A  0.395
1989 Haber DA, Housman DE. MspI/HpaII polymorphism in the human multidrug resistance gene 1. Nucleic Acids Research. 17: 10142. PMID 2481261 DOI: 10.1093/Nar/17.23.10142  0.466
1989 Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Molecular and Cellular Biology. 9: 1346-50. PMID 2471060 DOI: 10.1128/Mcb.9.3.1346  0.509
1982 Haber DA, Schimke RT. Chromosome-mediated transfer and amplification of an altered mouse dihydrofolate reductase gene. Somatic Cell Genetics. 8: 499-508. PMID 7123452 DOI: 10.1007/Bf01538710  0.529
1981 Haber DA, Schimke RT. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell. 26: 355-62. PMID 7326744 DOI: 10.1016/0092-8674(81)90204-X  0.528
1981 Haber DA, Beverley SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. The Journal of Biological Chemistry. 256: 9501-10. PMID 7287696  0.455
Show low-probability matches.